High-Flying Drug Stock Can Head Even Higher

Shares of Sarepta Therapeutics soared Wednesday on news of a successful clinical trial for a muscular dystrophy drug. The stock has further to climb.

There finally may be hope for those suffering from Duchenne muscular dystrophy (DMD), a fatal-muscle-wasting disease that afflicts more than 10,000 in the U.S. alone.

The results released today of a clinical trial on a drug developed by Sarepta Therapeutics (SRPT) for the treatment of DMD were very favorable and could pave the way for accelerated approval next year by the Food and Drug Administration.